INTRODUCTION: A central pancreatectomy is a parenchyma-sparing procedure that is performed to reduce long-term endocrine and exocrine insufficiency. METHOD: In this study, we analyzed the perioperative course, the frequency of postoperative onset of diabetes mellitus, and long-term change of body weight in patients undergoing a central pancreatectomy, in comparison to the patients undergoing a distal pancreatectomy for low-grade neoplasms including cystic neoplasms and neuroendocrine tumors. RESULTS AND DISCUSSION: The rate of postoperative complications including grade B/C pancreatic fistula was no different between both groups. Only one patient undergoing a central pancreatectomy (4.7%) developed new onset of mild diabetes, whereas 35% in the distal pancreatectomy group developed new onset or worsening diabetes (p = 0.0129). The body weight in the distal pancreatectomy group was significant lower than that in the central pancreatectomy group at 1 and 2 years after surgery (1 year; P < 0.0001, 2 years; P = 0.0055), and the body weight in the patients undergoing a central pancreatectomy improved to preoperative values within 2 years after surgery. CONCLUSION: A central pancreatectomy is a safe procedure for the treatment of low-grade malignant neoplasms in the pancreatic body; the rate of onset of diabetes is minimal, and the body weight improves early in the postoperative course.
INTRODUCTION: A central pancreatectomy is a parenchyma-sparing procedure that is performed to reduce long-term endocrine and exocrine insufficiency. METHOD: In this study, we analyzed the perioperative course, the frequency of postoperative onset of diabetes mellitus, and long-term change of body weight in patients undergoing a central pancreatectomy, in comparison to the patients undergoing a distal pancreatectomy for low-grade neoplasms including cystic neoplasms and neuroendocrine tumors. RESULTS AND DISCUSSION: The rate of postoperative complications including grade B/C pancreatic fistula was no different between both groups. Only one patient undergoing a central pancreatectomy (4.7%) developed new onset of mild diabetes, whereas 35% in the distal pancreatectomy group developed new onset or worsening diabetes (p = 0.0129). The body weight in the distal pancreatectomy group was significant lower than that in the central pancreatectomy group at 1 and 2 years after surgery (1 year; P < 0.0001, 2 years; P = 0.0055), and the body weight in the patients undergoing a central pancreatectomy improved to preoperative values within 2 years after surgery. CONCLUSION: A central pancreatectomy is a safe procedure for the treatment of low-grade malignant neoplasms in the pancreatic body; the rate of onset of diabetes is minimal, and the body weight improves early in the postoperative course.
Authors: Robert R Hutchins; Richard S Hart; Marc Pacifico; Nicholas J Bradley; Robin C N Williamson Journal: Ann Surg Date: 2002-11 Impact factor: 12.969
Authors: Michael W Müller; Helmut Friess; Jörg Kleeff; Ulf Hinz; Moritz N Wente; Daniel Paramythiotis; Pascal O Berberat; Güralp O Ceyhan; Markus W Büchler Journal: Ann Surg Date: 2006-12 Impact factor: 12.969
Authors: Jonathan King; Kevork Kazanjian; J Matsumoto; Howard A Reber; Michael W Yeh; O Joe Hines; Guido Eibl Journal: J Gastrointest Surg Date: 2008-06-10 Impact factor: 3.452
Authors: Daniel Leonard; Jacques Baulieux; Agnès Rode; Vincent Garbit; Eric De La Roche; Christian Ducerf; Jean-Yves Mabrut Journal: J Hepatobiliary Pancreat Surg Date: 2007-11-30
Authors: M Lombardi; N De Lio; N Funel; C Sardella; D Russo; C Urbani; G Rossi; D Campani; E Martino; C Marcocci; U Boggi; F Bogazzi Journal: J Endocrinol Invest Date: 2014-12-12 Impact factor: 4.256